Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Vanguard MSCI Index International Shares ETF

VGS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

Liontown Resources Limited

LTR

Liontown Resources Ltd. engages in the exploration and evaluation of minerals. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-27. The firm controls two major hard rock lithium deposits. The firm's projects include Kathleen Valley Project and Buldania Project. The Kathleen Valley Project is located in an established mining region about 60 kilometers north of Leinster and 680 kilometers north-east of Perth, Western Australia. The Kathleen Valley Lithium Project is a Tier-1 battery metals asset with excellent grade and scale in one of world's best mining districts. The Buldania Project is in the Eastern Goldfields Province of Western Australia, approximately 600 kilometers east of Perth. The Project is close to major road and rail infrastructure with direct access to the Port of Esperance 200 kilometers to the south. The firm's downstream expansion project includes investigating the potential for an integrated refinery to upgrade its spodumene from the Kathleen Valley mine to higher value lithium products.

VanEck Morningstar Wide Moat ETF

MOAT

MOAT.AX was created on 2015-06-26 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The VanEck Morningstar Wide Moat ETF seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Morningstar Wide Moat Focus Index.

Botanix Pharmaceuticals Ltd

BOT

Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the provision of business of researching and developing dermatology and antimicrobial products. The company is headquartered in Perth, Western Australia. The firm is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. The company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. The company also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.